GlassScriptPhysician profile
Jill T Honkamp
NPI 1497884340
$6,259.11
in general payments reported to CMS, 2019-2025
27 companies · $599 in 2025
The $599 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,013 · 2020: $96.90 · 2021: $153 · 2022: $340 · 2023: $564 · 2024: $493 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,538 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,537.95 |
| Education | $118.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,918.47 | 2019-2021 | |
| Abbvie INC. | $404.96 | 2019-2025 | |
| Pfizer INC. | $321.83 | 2019-2023 | |
| Astellas Pharma US INC | $280.58 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $157.96 | 2023-2025 | Myfembree |
| Medtronic, INC. | $126.27 | 2022-2024 | Ligasure, V-Loc 180 |
| Exeltis, USA INC. | $116.78 | 2023-2025 | Slynd |
| Sage Therapeutics, LLC | $114.05 | 2024-2025 | Zurzuvae |
| Organon LLC | $112.88 | 2022-2024 | Nexplanon, Nuvaring |
| Daiichi Sankyo INC. | $110.29 | 2024-2025 | Injectafer |
| Axonics, INC. | $107.74 | 2022-2023 | Axonics |
| Exact Sciences Corporation | $57.01 | 2023-2025 | Cologuard Collection Kit |
| Pharmacosmos Therapeutics INC. | $48.17 | 2024-2025 | Monoferric |
| Conmed Corporation | $45.45 | 2019 | |
| Ethicon US, LLC | $45.33 | 2022-2024 | Dermabond Prineo, Stratafix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $39.36 | 2022-2024 | Fluent Fluid Management System, Myosure Tissue Removal Device, Novasure |
| Mayne Pharma Commercial LLC | $33.89 | 2023 | |
| Covidien LP | $33.46 | 2019 | |
| Esperion Therapeutics, INC. | $28.45 | 2024 | Nexletol |
| Therapeuticsmd, INC. | $27.82 | 2019-2021 | |
| Smith+Nephew, INC. | $22.68 | 2025 | Pico 14 |
| Vertex Pharmaceuticals Incorporated | $20.64 | 2025 | |
| Tersera Therapeutics LLC | $18.62 | 2024 | Zoladex |
| Channel Medsystems, INC. | $18.00 | 2022 | |
| Myovant Sciences INC. | $17.38 | 2022 | |
| Lilly USA, LLC | $16.78 | 2025 | Zepbound, Mounjaro |
| Supernus Pharmaceuticals, INC. | $14.26 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Honkamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.